Clinical Trials
81 trialsNCT07444710 2026-05-13
Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma
National Cancer Institute (NCI)
Phase 1 Not yet recruiting
NCT04161248 2026-05-12
Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
Canadian Cancer Trials Group
Phase EARLY_PHASE1 Active not recruiting
NCT06230224 2026-05-11
OLYMPIA-4
Regeneron Pharmaceuticals
Phase 3 Active not recruiting
NCT04442022 2026-05-06
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Karyopharm Therapeutics Inc
Phase 2/3 Active not recruiting
NCT02436707 2026-04-20
Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
Canadian Cancer Trials Group
Phase 2 Active not recruiting
NCT03418038 2026-04-16
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Mayo Clinic
Phase 2 Recruiting
NCT05498220 2026-04-16
Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Terminated
NCT00931645 2026-04-02
Auto-LLC 2001
University Hospital, Caen
Phase 3 Completed
NCT04328844 2026-03-30
A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
iOnctura
Phase 1 Active not recruiting
NCT01846390 2026-03-27
Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma
Canadian Cancer Trials Group
Phase 1 Completed
NCT05502250 2026-03-06
HOVON164HL
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 2 Active not recruiting
NCT02858804 2026-02-11
BDH-MCL01
Institute of Hematology & Blood Diseases Hospital, China
Phase 4 Completed
NCT05180097 2026-02-02
Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma
Canadian Cancer Trials Group
Phase 2 Recruiting
NCT02896582 2026-01-14
LyMa101
The Lymphoma Academic Research Organisation
Phase 2 Completed
NCT03013218 2025-08-01
A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)
ALX Oncology Inc.
Phase 1 Completed
NCT02750670 2025-06-22
Obinutuzumab in Combination With GDP Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
University Health Network, Toronto
Phase 2 Completed
NCT02348216 2024-06-04
ZUMA-1
Gilead Sciences
Phase 1/2 Completed
NCT01626664 2024-04-25
KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)
Kyowa Kirin Co., Ltd.
Phase 2 Completed
NCT03246750 2024-04-17
B-MAD Chemotherapy in Newly-diagnosed Extranodal NK/ T-cell Lymphoma
The Thai Lymphoma Study Group
Phase 1/2 Completed
NCT01858922 2024-01-12
TXCH-HD-12A
Baylor College of Medicine
Phase 2 Completed
NCT00004192 2023-12-27
Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma
University of Nebraska
Phase 2 Completed
NCT00078949 2023-08-23
Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Canadian Cancer Trials Group
Phase 3 Completed
NCT05821192 2023-04-20
Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.
The First Hospital of Jilin University
Phase NA Unknown
NCT05441761 2022-07-01
Mitoxantrone Hydrochloride Liposomes in Combination With GDP in Relapsed/Refractory PTCL
Peking Union Medical College Hospital
Phase 1/2 Unknown
NCT01655225 2022-04-08
A Study of LY3023414 in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT03837873 2022-01-26
DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Unknown
NCT02741388 2021-12-07
SELINDA
The Lymphoma Academic Research Organisation
Phase 1 Completed
NCT04882163 2021-10-05
Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma
Celgene
Phase 1/2 Withdrawn
NCT04999878 2021-08-11
RUE-DDGP
Zhengzhou University
Phase 4 Unknown
NCT00302003 2021-03-30
Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma
Children's Oncology Group
Phase 3 Completed
NCT00577993 2020-11-16
Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients
M.D. Anderson Cancer Center
Phase 3 Completed
NCT04230330 2020-11-05
Nivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell Lymphoma
National Cancer Centre, Singapore
Phase 1 Withdrawn
NCT03027284 2020-05-19
A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer
Eli Lilly and Company
Phase 1 Completed
NCT00014209 2020-04-09
Combination Chemotherapy in Hodgkin's Disease or Non-Hodgkin's Lymphoma Not Responding to Previous Treatment
Canadian Cancer Trials Group
Phase 2 Completed
NCT00003397 2019-11-04
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
University of Maryland, Baltimore
Phase 2 Completed
NCT00003402 2019-10-17
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
University of Maryland, Baltimore
Phase 2 Completed
NCT02060656 2019-09-19
LEGEND
Royal Marsden NHS Foundation Trust
Phase 2 Unknown
NCT00732498 2019-09-04
ESHAP
University of Arizona
Phase 2 Completed
NCT02243436 2019-04-24
Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 1/2 Completed
NCT00002835 2018-11-15
Combination Chemotherapy in Treating Patients With Lymphoma
M.D. Anderson Cancer Center
Phase 3 Completed
NCT00002565 2018-11-14
Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma
M.D. Anderson Cancer Center
Phase 3 Completed
NCT00002461 2018-08-17
Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma
Montefiore Medical Center
Phase 2 Completed
NCT03623087 2018-08-14
SIMPLE Chemotherapy for NK Lymphoma/Leukaemia
The University of Hong Kong
Phase 3 Unknown
NCT03071822 2018-06-11
Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas
The University of Hong Kong
Phase 4 Unknown
NCT01719835 2018-03-15
CHEMO-T
Royal Marsden NHS Foundation Trust
Phase 2 Unknown
NCT02280993 2018-03-13
Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 1 Unknown
NCT02983097 2018-01-19
R²-DHAP
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Phase 1/2 Terminated
NCT02542111 2017-11-14
A Study of Bortezomib Plus GDP in the Treatment of Refractory and Relapsed Non-GCB DLBCL
Ruijin Hospital
Phase 2 Unknown
NCT00238368 2017-11-06
Fludeoxyglucose F 18 Positron Emission Tomography in Predicting Risk of Relapse in Patients With Non-Hodgkin's Lymphoma Who Are Undergoing Combination Chemotherapy With or Without Autologous Stem Cell or Bone Marrow Transplant
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00025259 2017-04-12
Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease
Children's Oncology Group
Phase 3 Completed